Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD, Inc. (NSPR) is a medical device company whose news flow centers on its CGuard® Prime carotid stent system and proprietary MicroNet™ mesh technology for stroke prevention. Company press releases and SEC filings describe InspireMD as the developer of CGuard® Prime for the treatment of carotid artery stenosis, with a focus on making its products a standard approach in carotid stenting.
News about InspireMD often covers clinical milestones and peer-reviewed publications. For example, the company announced that results from its C-GUARDIANS pivotal trial of the CGuard® Prime carotid stent system were published in the Journal of the American College of Cardiology, with data showing low rates of disabling stroke or myocardial infarction through 30 days and low ipsilateral stroke rates through one year. InspireMD has also highlighted external clinical evidence such as the CREST-2 study in the New England Journal of Medicine, which it views as supportive of carotid artery stenting combined with medical therapy.
Investors following NSPR can also expect updates on regulatory and commercial developments. Recent filings report FDA PMA approval for the CGuard Prime Carotid Stent System in the United States and subsequent announcements of a U.S. commercial launch. Quarterly earnings releases describe the impact of CGuard Prime on revenue and provide commentary on procedure volumes and expansion of the company’s commercial team.
Additional news items include capital-raising transactions, such as private placements and warrant exercises, as well as changes in board composition and senior medical leadership. Together, these updates give readers insight into InspireMD’s clinical progress, regulatory status, commercialization efforts, and corporate governance. This page aggregates such NSPR news so readers can review the company’s key announcements in one place.
InspireMD (Nasdaq: NSPR) will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:30 PM ET. The company, developer of the CGuard Prime carotid stent system, said a live audio webcast and a replay will be available on its Investor Calendar page. Investors can access the event via the provided webcast link and listen live or via the replay on the company website.
InspireMD (Nasdaq: NSPR) reported third quarter 2025 results and operational milestones on November 4, 2025. Total revenue rose 39% to $2.5M versus prior year, with U.S. revenue $497,000 and international $2.0M. The company initiated the U.S. commercial launch of CGuard Prime, recording over 100 U.S. procedures in leading hospitals. Gross profit was $864,000. Operating expenses increased to $13.9M (up 57%) driven by U.S. commercial hires and U.S. headquarters costs. Net loss was $12.7M, $0.17 per share versus $7.9M, $0.16 a year earlier. Cash and marketable securities totaled $63.4M, supported by $58M in gross proceeds raised in July. Management hosted a conference call on November 4, 2025 to discuss results.
InspireMD (Nasdaq: NSPR) appointed Peter A. Soukas, M.D. as Chief Medical Officer effective Nov 3, 2025 to advance clinical and medical strategy around its CGuard Prime carotid stent system.
Dr. Soukas will help support the planned U.S. launch, maintain his clinical practice, and bring academic and trial experience as Director of Vascular Medicine at The Miriam Hospital and Associate Professor at Brown University.
InspireMD (Nasdaq: NSPR) announced it will release its third quarter 2025 financial results on Tuesday, November 4, 2025.
The company will host a conference call and webcast on November 4, 2025 at 8:30 a.m. Eastern Time to review results and recent highlights. Domestic callers may dial 1-800-579-2543; international callers may dial 1-785-424-1789. Investors can join the live webinar via InspireMD’s website or the provided webcast registration link. A replay will be available shortly after the call and archived on the company website.
InspireMD (Nasdaq: NSPR) announced that its Compensation Committee approved inducement grants of 40,513 restricted shares to three new non-executive employees, granted outside the 2021 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4).
The grants were made under InspireMD's 2024 Inducement Plan with a grant date of October 7, 2025. The restricted stock vests over three years: one-third on the first anniversary and the remainder in two equal installments on the second and third anniversaries, subject to continued employment.
InspireMD (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system, has announced the approval of inducement grants for five new non-executive employees. The Compensation Committee approved a total of 88,324 shares of restricted stock under the company's 2024 Inducement Plan.
The grants, made outside the company's 2021 Equity Incentive Plan, have a grant date of September 24, 2025. The restricted stock follows a three-year vesting schedule, with one-third vesting on the first anniversary and the remaining portions vesting equally on the second and third anniversaries, contingent on continued employment.
InspireMD (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system, has appointed Dan Dearen to its Board of Directors. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors.
Dearen's notable achievements include serving as President, co-Founder, and CFO of Axonics, Inc., which was acquired by Boston Scientific for $3.7 billion in November 2024. He also held key positions at Vessix Vascular (acquired by Boston Scientific for $425 million) and currently serves on the boards of JenaValve Technology and BetaBionics.
This appointment comes at a strategic time as InspireMD continues its U.S. commercial launch of CGuard Prime, following FDA approval.
InspireMD (NASDAQ:NSPR), the developer of the CGuard® Prime carotid stent system for stroke prevention, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10th at 10:00am ET.
Investors can access both the live audio webcast and replay of the presentation through the company's website investor calendar section at inspiremd.com/investors/investor-calendar/.
Biobeat Technologies has appointed Raymond W. Cohen as Chairman of the Board of Directors. The company, which develops wearable medical devices, has received FDA clearance for its innovative patch device that monitors multiple physiological parameters including continuous cuff-less ambulatory blood pressure.
Cohen brings over 40 years of life science industry experience, notably as co-founder and CEO of Axonics, which was acquired by Boston Scientific for $3.7 billion in 2024. Under his leadership, Axonics generated over $1 billion in revenue within four years of commercial launch. Most recently, as chairman of SoniVie, he led its sale to Boston Scientific for $600 million in March 2025.
InspireMD (Nasdaq: NSPR) reported Q2 2025 financial results, marking a transformative period highlighted by the FDA approval and U.S. commercial launch of their CGuard Prime carotid stent system. The company secured $58 million in gross proceeds through equity private placement and warrant exercises.
Q2 2025 revenue increased 2.3% to $1.78 million, while operating expenses rose 55.2% to $13.33 million due to U.S. sales force expansion. The company reported a net loss of $13.15 million ($0.26 per share). Cash position stood at $19.37 million as of June 30, 2025. Additional milestones include CE Mark approval for CGuard Prime EPS and key leadership appointments.